Enhancement of Macular Pigment Density by Oral Lutein Supplementation (EMPOLS)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary objective of EMPOLS is an increase in macular pigment density (MPD) and contrast sensitivity (CS) after six months supplementation of oral non-compound ester Lutein 10 mg daily, contained in VitaluxPlus®. Primary variable for a significant change will be 10% increase compared to baseline MPD.
The measurement will be carried out by means of a modified confocal scanning laser ophthalmoscope (HRA) recording autofluorescence images at 488 nm and 514 nm 6. MPD is determined on MPD maps within 0.5 degrees around the center of the fovea. All MPD measurements and photographs will by performed by the Bern Photographic Reading Center (BPRC). Complete examination of study patients comprises testing of standardized visual acuity (ETDRS-VA), visual contrast sensitivity (CS), biomicroscopy, fundus photography, and a blood sample. Participating patients also have to fill out a food frequency questionnaire (FFQ-Bern) allowing for correction of additional lutein intake by regular diet. Moreover possible confounding factors e.g. as sunlight exposure or smoking habits will be assessed. Secondary objective of EMPOLS is the effect of oral non-compound ester lutein supplementation on CS and ETDRS-VA during one year. The variable for a significant change in ETDRS-VA is loss or gain of 7 letters on the ETDRS chart, for a change in CS: loss or gain of at least four letters on the Pelli-Robson CS Chart. Additionally, serum carotenoid levels of lutein will be determined by high performance liquid chromatography (HPLC) for each visit 1.
| Condition | Intervention |
|---|---|
|
Age-Related Maculopathies |
Dietary Supplement: VitaluxPlus® Dietary Supplement: Omega 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Bio-availability Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Enhancement of Macular Pigment Density by Oral Lutein Supplementation |
- Macular pigment density, contrast sensitivity [ Time Frame: 6 months ] [ Designated as safety issue: No ]
| Enrollment: | 80 |
| Study Start Date: | July 2007 |
| Study Completion Date: | December 2009 |
| Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
VitaluxPlus®
|
Dietary Supplement: VitaluxPlus®
1 tablet daily
|
| Active Comparator: 2 |
Dietary Supplement: Omega 3
1 tablet daily
|
Eligibility| Ages Eligible for Study: | 50 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- age related maculopathy
Exclusion Criteria:
- exudative age related degeneration
Contacts and Locations| Switzerland | |
| Klinik und Poliklinik für Augenheilkunde, University Bern | |
| Bern, Switzerland | |
| Study Director: | Sebastian Wolf, MD | University of Bern |
| Principal Investigator: | Ute Wolf-Schnurrbusch, MD | University of Bern |
More Information
No publications provided
| Responsible Party: | Sebastian Wolf, Director, University Hospital Inselspital, Berne |
| ClinicalTrials.gov Identifier: | NCT00563979 History of Changes |
| Other Study ID Numbers: | KEK 152/07 |
| Study First Received: | November 26, 2007 |
| Last Updated: | October 26, 2011 |
| Health Authority: | Switzerland: Ethikkommission |
Keywords provided by University Hospital Inselspital, Berne:
|
AMD supplementation macular pigment |
Additional relevant MeSH terms:
|
Macular Degeneration Retinal Degeneration Retinal Diseases Eye Diseases |
ClinicalTrials.gov processed this record on May 21, 2013